Dataset from A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.

B7451013是一项3期临床试验，旨在评估PF-04965842在12岁及以上、最低体重40kg的中度至重度特应性皮炎（atopic dermatitis）患者中的应用。本试验将在为期12周的研究周期内，对比PF-04965842两种给药剂量强度（100mg与200mg，每日一次口服）与安慰剂的疗效与安全性。符合入组条件的患者在完成12周治疗后，可选择进入长期扩展研究。